147 days ago • Posted by William Ramstein

Endocannabinoid biotech firms gain from cannabis surge

Drugmakers that target the endocannabinoid system -- which is believed to play a key role in regulating body weight and controlling energy balance -- have skyrocketed in 2021. While those biotechs wouldn’t necessarily benefit from any legislative push for the pot industry, analysts say the stocks have jumped on the idea that they would be associated somehow with cannabis. And they are not. Tilray, Sundial Growers , Corbus, Artelo, Zynerba. Source: Bloomberg

bg_nwsletter